Nasdaq · Healthcare
OCULAR THERAPEUTIX, INC (OCUL)
As-reported financials and recent SEC filings for OCULAR THERAPEUTIX, INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$52.0M
Net income
$-265.9M
Net margin
—
Diluted EPS
$-1.42
ROE
-40.6%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M |
| Gross profit | $45.4M | $58.1M | $53.2M | $47.0M | $39.1M |
| Operating income | $-270.0M | $-171.8M | $-82.4M | $-78.7M | $-78.0M |
| Net income | $-265.9M | $-193.5M | $-80.7M | $-71.0M | $-6.6M |
| Diluted EPS | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-18
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →Largest Healthcare peers
Go deeper on OCUL
Search OCULAR THERAPEUTIX, INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.